# DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

Source: https://onco.cc/trials/nct06539182/  
OnCo record `nct06539182` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of DZD8586 in chronic lymphocytic leukaemia, run by Dizal Pharmaceuticals, now recruiting.

## Summary

DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) is a phase 2 interventional study registered as NCT06539182 by Dizal Pharmaceuticals, with 155 participants planned, started 2024-04-29 and due to reach its primary completion in 2027-09. Interventions recorded: DZD8586.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06539182
- Phase: 2
- Setting: A Phase 2, Open-label, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of DZD8586 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Sponsor: Dizal Pharmaceuticals
- Enrolled: 155

## Sources

- ClinicalTrials.gov NCT06539182: https://clinicaltrials.gov/study/NCT06539182

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [DZD8586](https://onco.cc/drugs/dzd8586/)
- companies: [Dizal Pharmaceutical](https://onco.cc/companies/dizal/)

---
JSON: https://onco.cc/api/v1/entities/nct06539182.json